68 results
P
pacientes que passed a spontaneous breathing trial
I/C
cough peak flow assessment, extubation outcome
O
diagnostic performance of the cough peak flow
P
pacientes con COVID-19
I/C
inhibidores de la enzima convertidora de angiotensina, bloqueadores del receptor de angiotensina II, placebo o ningún tratamiento
O
efectos sobre la COVID-19
P
people being investigated for tuberculosis
I/C
Xpert MTB/RIF, smear microscopy
O
mortality, proportion of participants starting tuberculosis treatment who had a successful treatment outcome, proportion of participants who were treated for tuberculosis, proportion of participants with bacteriological confirmation who were lost to follow-up pre-treatment, proportion of treated participants who had bacteriological confirmation
P
I/C
O
P
care dyads, person with ostomy, caregiver
I/C
permanent discharge ostomy, no ostomy
O
rejection of bodily changes and sexual dysfunction, assertive and effective family care
P
616 participants
I/C
prednisolone/prednisone, ACTH/tetracosactide
O
electroclinical response, adverse events
P
older adults without cognitive impairment
I/C
anticholinergic medications, cognitive decline or dementia
O
risk of cognitive decline or dementia
P
adolescents, dual users (combustible- plus electronic- cigarettes users), electronic nicotine delivery systems (ENDS) users, never- or past- electronic nicotine delivery systems users
I/C
electronic nicotine delivery systems (ENDS), c-cigarettes, c-cig, dual users (combustible- plus electronic- cigarettes users) versus combustible-cigarettes users, electronic nicotine delivery systems (ENDS) users versus never- or past- electronic nicotine delivery systems users
O
proportion of complete or partial substitution of conventional to electronic cigarettes, odds ratio of quitting combustible cigarettes among electronic nicotine delivery systems users, prevalence of electronic cigarettes use, relationship between consumption and price increase of electronic and combustible cigarettes